Imuldosa has been approved by the FDA for various chronic inflammatory conditions, including psoriasis, psoriatic arthritis, Crohn’s disease, and ulcerative colitis. This Medicaid-covered option is designed to be a more affordable treatment.

Prescribing Imuldosa through Fidelis Specialty Pharmacy keeps GI practices streamlined, reduces administrative burdens, accelerates therapy access, and improve patient adherence.

Fidelis provides dedicated support for:

• Benefits investigation

• Prior authorizations

• Patient education

• Refill management

• Ongoing coordination

Our high-touch service model ensures physicians, office staff, and patients have direct access to experienced specialty pharmacy professionals who understand the complexities of GI therapies and chronic disease management.

Working with Fidelis Specialty Pharmacy to prescribe Imuldosa:

• Improves patient access and affordability

• Expands treatment options when payer restrictions exist

• Supports continuity of care for chronic GI patients

• Reduces delays caused by step therapy or formulary barriers

• Provides clinically appropriate alternatives while maintaining quality standards

Fidelis offers:

• High-touch specialty pharmacy support

• Personalized patient care coordination

• Rapid benefits investigation

• Fast prior authorization support

• Refill adherence management

• Ongoing patient communication

• Reduced time from prescription to therapy

Your practice can count on:

• Direct access to live team members

• Dedicated account support

• Pharmacist accessibility

• Personalized coordination with clinic staff

• Boutique-level service with specialty expertise

• Specialty medication expertise

• Chronic disease management

• Infusion and self-injectable coordination

• Clinical monitoring support

• Patient education